[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-350748-105":59,"doc-detail-350748-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","driving-tumor-associated-macrophages-to-a-cxcl9-hispp1-low-phenotype-eliminates-pancreatic-cancer","Driving tumor-associated macrophages to a CXCL9 Hi/SPP1 Low phenotype eliminates pancreatic cancer","","Pancreatic ductal adenocarcinoma (PDAC) has limited treatment options and poor survival, driven in part by immunosuppressive tumor microenvironment interactions. The CXCL9-low, SPP1-high tumor-associated myeloid cell phenotype is highly abundant and contributes to disease progression. Nguyen and colleagues develop a myeloid cell-targeting cyclodextrin nanoformulation (CANDI470) to increase CXCL9 while reducing SPP1 in tumor-associated myeloid cells. In murine PDAC models, this strategy boosts immune responses and delivers striking therapeutic efficacy, including cures, even as monotherapy.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/driving-tumor-associated-macrophages-to-a-cxcl9-hispp1-low-phenotype-eliminates-pancreatic-cancer/350748/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/driving-tumor-associated-macrophages-to-a-cxcl9-hispp1-low-phenotype-eliminates-pancreatic-cancer/350748.png","ImageObject",300,407,{"name":92,"@type":93},"LangkahRina","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-06","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What immunosuppressive myeloid phenotype is implicated in PDAC progression?","Question",{"text":112,"@type":113},"Tumor-associated myeloid cells with a CXCL9-low, SPP1-high phenotype are described as highly abundant in PDAC and linked to poor prognosis.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What therapeutic approach do the authors develop to modulate these cells?",{"text":117,"@type":113},"They design a myeloid cell-targeting nanoformulation (CANDI470) intended to increase CXCL9 expression and reduce SPP1 levels in tumor-associated myeloid cells.",{"name":119,"@type":110,"acceptedAnswer":120},"How effective is the nanoformulation in treating PDAC models?",{"text":121,"@type":113},"The strategy enhances immune responses and shows remarkable therapeutic efficacy in murine PDAC models, including cures, even when used as monotherapy.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},350748,1790170896,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":46,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":31,"preview_page_count":19,"preview_urls":144},962090893776,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Article  \nDriving tumor-associated macrophages to a CXCL9 Hi/SPP1 Low phenotype eliminates pancreatic cancer  \nGraphical abstract Authors  \nYen T.M. Nguyen, Marc Pfefferl´e, Juhyun Oh, ..., Andrew S. Liss, Mikael J. Pittet, Ralph Weissleder  \nCorrespondence  \n[rweissleder@mgh.harvard.edu](rweissleder@mgh.harvard.edu)  \nIn brief  \nImmunosuppressive CXCL9Lo/SPP1Hi myeloid cells are highly abundant in PDAC, adding to the poor prognosis. Using the myeloid cell-targeting cyclodextrin nanoconstruct, Nguyen et al. found that simultaneously modulating CXCL9 and SPP1 through this single, systemically administered nanoformulation is highly effective in treating murine PDAC.  \nHighlights  \n• The immunosuppressive CXCL9Lo/SPP1Hi macrophage phenotype predominates in PDAC  \n• Cyclodextrin nanoconstructs carry payloads modulating both CXCL9 and SPP1  \n• Myeloid-targeting cyclodextrin nanoformula effectively treats PDAC in murine models  \nNguyen et al., 2026, Cell Reports Medicine 7, 102938  \nAugust 18, 2026 © 2026 The Author(s) . Published by Elsevier Inc.  \n[https://doi.org/10.1016/j.xcrm.2026.102938](https://doi.org/10.1016/j.xcrm.2026.102938)  \nll  \nll  \nOPEN ACCESS  \nArticle  \nDriving tumor-associated macrophages to a CXCL9Hi/SPP1Low phenotype eliminates pancreatic cancer  \nYen T. M. Nguyen,1 Marc Pfefferl´e,9,10 Juhyun Oh,1,2,11 Grant G. Simpson,1,11 Sierra A. Walker,1 Shingo Noguchi,1 Christopher S. Garris,1,2 Riley J. Deutsch-Williams,1 Pratyaksha Wirapati,5,6 Federico De Stefano,3 Marie Goemans,1 Rui Dai,1 Claudio Vinegoni,1 Carlos Fern´andez del Castillo,3 Andrew S. Liss,3 Mikael J. Pittet,5,6,7,8  \nand Ralph Weissleder1,2,4,12,*  \n1Center for Systems Biology, Massachusetts General Hospital, Boston, MA 02114, USA  \n2Department of Radiology, Harvard Medical School, Boston, MA 02115, USA  \n3Department of Surgery, Massachusetts General Hospital, Boston, MA 02114, USA  \n4Department of Systems Biology, Harvard Medical School, Boston, MA 02115, USA  \n5Department of Pathology and Immunology, and Center for Translational Oncohaematology Research, University of Geneva, 1211 Geneva, Switzerland  \n6AGORA Cancer Research Center, and Swiss Cancer Center Leman, 1011 Lausanne, Switzerland  \n7Ludwig Institute for Cancer Research, 1011 Lausanne, Switzerland  \n8Department of Oncology, Geneva University Hospitals, 1211 Geneva, Switzerland  \n9Department of Gastroenterology and Hepatology, University Hospital Lausanne – Centre Hospitalier Universitaire Vaudois (CHUV), 1011 Lausanne, Switzerland  \n10Department of Internal Medicine, University Hospital Lausanne – Centre Hospitalier Universitaire Vaudois (CHUV), 1011 Lausanne, Switzerland  \n11These authors contributed equally  \n12Lead contact  \n*Correspondence: [rweissleder@mgh.harvard.edu](rweissleder@mgh.harvard.edu)[ ](rweissleder@mgh.harvard.edu)[https://doi.org/10.1016/j.xcrm.2026.102938](https://doi.org/10.1016/j.xcrm.2026.102938)  \nSUMMARY  \nPancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest cancers, with limited therapeutic options. Recent studies reveal the complex PDAC microenvironment, which fosters interactions between various cell types that contribute to immunosuppression. Among these, tumor-associated myeloid cells with a CXCL9-low, SPP1-high phenotype are particularly abundant and play a significant role in promoting disease progression. We hypothesize that targeting these cells can reprogram the tumor microenvironment and improve survival outcomes. To test this, we develop a myeloid cell-targeting nanoformulation, CANDI470, designed to increase CXCL9 expression and reduce SPP1 levels in tumor-associated myeloid cells. Our results demonstrate that this approach not only enhances immune responses but also achieves remarkable therapeutic efficacy, including cures in murine PDAC models, even when used asa monotherapy. This myeloid cell modulation strategy represents a promising therapeutic avenue for PDAC, offering hope for improved treatment for this otherwise difficult-to-t","cbCaispLt7BeT1Xm","https://ap.wps.com/l/cbCaispLt7BeT1Xm","pdf",7080754,"English","# Summary\n# Highlights\n# Introduction\n# Summary and hypothesis\n# Therapeutic strategy and nanoformulation","[{\"question\":\"What immunosuppressive myeloid phenotype is implicated in PDAC progression?\",\"answer\":\"Tumor-associated myeloid cells with a CXCL9-low, SPP1-high phenotype are described as highly abundant in PDAC and linked to poor prognosis.\"},{\"question\":\"What therapeutic approach do the authors develop to modulate these cells?\",\"answer\":\"They design a myeloid cell-targeting nanoformulation (CANDI470) intended to increase CXCL9 expression and reduce SPP1 levels in tumor-associated myeloid cells.\"},{\"question\":\"How effective is the nanoformulation in treating PDAC models?\",\"answer\":\"The strategy enhances immune responses and shows remarkable therapeutic efficacy in murine PDAC models, including cures, even when used as monotherapy.\"}]","Driving tumor-associated macrophages to a CXCL9 Hi/SPP1 Low phenotype eliminates pancreatic cancer | PDF",1790090883,[145,149,153,157],{"page_no":8,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5988e7177f4432a67c535576d38aeeef.webp",983,1276,{"page_no":14,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/873f3875c7b2e82f5cb1c8f76bc406ab.webp",982,1275,{"page_no":81,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/117bd559ebe94b6faf4686604863cf5f.webp",981,1273,{"page_no":19,"url":158,"width":159,"height":160},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3e7007f55638e1d61df8f80b15ba2e71.webp",980,1272]